Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab.
BMJ Case Rep
; 20182018 Feb 05.
Article
en En
| MEDLINE
| ID: mdl-29437743
Minimal change disease (MCD) is usually steroid sensitive, although in case of steroid dependent and multiple relapses we can struggle with different immunosuppressive agents, sometimes with no response. Rituximab has been emerging as an alternative therapeutic option.We describe a case of a young patient with MCD that had frequent relapses and steroid dependency, with no response to several immunosuppressive agents during 15 years of disease. He was kept under high-dose steroids and ciclosporin. He started treatment with rituximab (two administrations of 1 g 2 weeks apart, repeating after 6 months). The steroids dose was gradually reduced and the ciclosporin was stopped. During the entire 2 years follow-up period, he remained in remission and had no adverse events.This remarkable outcome reinforces the option of using rituximab in difficult cases, allowing the reduction of steroid burden and its adverse effects, which is of extreme importance, especially in young patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esteroides
/
Inducción de Remisión
/
Trastornos Relacionados con Sustancias
/
Rituximab
/
Factores Inmunológicos
/
Nefrosis Lipoidea
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
BMJ Case Rep
Año:
2018
Tipo del documento:
Article
País de afiliación:
Portugal
Pais de publicación:
Reino Unido